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Progress and Hurdles for Follow-on Biologics

tion are likely to reduce the market penetration of interchangeable biologics.
The challenges to achieving
savings from follow-on biologics
are large but not insurmountable. First, market-entry hurdles
should be low enough to ensure
that enough companies compete
to affect prices. Public investment
in technological advances that
can support biosimilar development, such as advancing knowledge about glycosylating human
proteins in yeast, can aid all
manufacturers. The
An audio interview
FDA can help by
with Dr. Kesselheim
promulgating prodis available at NEJM.org
uct-specific guidance on how companies can
demonstrate biosimilarity or interchangeability, to reduce the
disadvantages for the first companies to try. Legislators may also
need to reexamine the process
for exchanging information about
potentially infringing patents, to
ensure that innovator manufacturers cannot unreasonably delay
the process in order to extend
their market exclusivity, and to
prevent biosimilar manufacturers from entering into anticompetitive settlements. Such settle-

ments have bedeviled the generic
small-molecule drug industry but,
since 2003, have had to be reported to the Federal Trade
Commission for evaluation of
their anticompetitive effects. This
requirement may have to be extended to biologic drugs.
Innovative approaches will be
required to ensure mandatory,
rigorous postapproval research
on the safety and effectiveness of
biosimilars compared with their
innovator predecessors in order
to promote confidence in these
new products. Over the long term,
attention to both these areas will
help ensure that U.S. patients benefit from appropriate price reductions for older biologic drugs
that are essential for their clinical care. At the same time, fair
but appropriately limited periods of exclusivity will reward
the innovators of the original
products while also spurring them
to create new products rather
than prolong exclusivity rights
over older ones long after such
monopolies should have come to
a natural end.
Disclosure forms provided by the authors
are available with the full text of this article
at NEJM.org.

From the Program on Regulation, Therapeutics, and Law (PORTAL), Division of
Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham
and Women’s Hospital and Harvard Medical School, Boston.
This article was published on May 6, 2015,
at NEJM.org.
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No Place to Call Home — Policies to Reduce ED Use
in Medicaid
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O

ne goal of Medicaid expansion under the Affordable
Care Act (ACA) is to provide lowincome, medically vulnerable
adults with a source of care outside the emergency department
(ED) and the means to pay for
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that care. Yet Medicaid expansion alone may not reduce ED
use among new enrollees. Although some research suggests
that Medicaid coverage is associated with reduced ED use, a
lottery-based, controlled study
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from Oregon found that newly
enrolled beneficiaries actually
increased their ED use, at least
temporarily.1 This finding is not
surprising, since health insurance reduces financial barriers
to being seen promptly, and the
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Reasons for Visiting the Emergency Department.
Data are from the National Health Interview Survey 2011–2013. Respondents could select more
than one answer. The sample is nonelderly adults (18 to 64 years of age) who have had an emergency department visit in the 12 months before they were interviewed. Persons who were known
to have been uninsured in the previous 12 months are excluded from the Private and Medicaid
categories.

newly enrolled Medicaid population has pent-up demand for care
and a high burden of chronic
disease. Although the contribution of ED use to cost growth is
sometimes exaggerated, it remains
a substantial source of health
care costs, representing at least
5 to 6% of U.S. health expenditures.2 Medicaid alone spends
$23 billion to $47 billion annually on ED care,2 and some of the
sickest Medicaid enrollees are
seen in the ED.
Broadly speaking, two approaches have been proposed for
reducing use of the ED in this
population. One focuses on making the ED more costly for patients to use; the other, on creating more robust alternatives to the
ED. Although not incompatible,
these approaches reflect different
beliefs about why Medicaid beneficiaries use the ED for medical
issues that could potentially be
addressed elsewhere.

By imposing steep copayments
for certain ED visits, the first approach aims to place responsibility on beneficiaries to make vigilant choices about when medical
issues require emergency attention (see graph for reasons patients visit the ED). For instance,
as part of its ACA Medicaid expansion, Indiana was granted
permission by the Centers for
Medicare and Medicaid Services
(CMS) to undertake a demonstration project involving charging
Medicaid recipients — many of
whom have family incomes below the federal poverty level —
$8 for their first visit to the ED
and $25 for subsequent visits
during the same year. The copayment applies when the visit is determined to be for “nonemergency” care, the patient did
not receive prior authorization
from his or her managed-care
organization, or the emergency
provider informed the patient that

n engl j med 372;25
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the problem could be managed
in another setting.
The logic behind increasing
cost sharing for “nonemergency”
ED visits is that it will motivate
patients to use lower-cost care
sites for most conditions, reserving the ED for times when they
truly need immediate attention.
This simple narrative, however,
is challenged by research. States
have had the option since 2005
of imposing copayments for Medicaid beneficiaries of up to $15
for nonemergency ED use, yet
the eight states that implemented
these programs saw no reduction
in ED visits by Medicaid recipients relative to other states.3
Case studies of Medicaid cost
sharing in other contexts similarly found that copayments
alone do not reduce ED visits for
diseases that can safely be treated in primary care settings. Analyses that have shown associations
between copayments and reductions in “unnecessary” ED use
are limited by their use of diagnosis or triage codes to determine retrospectively whether a
visit qualifies as “nonurgent.”
One explanation for these
findings is that even informed
patients cannot necessarily translate their symptoms and history
into a diagnosis, much less a
prognosis. Patients present to the
ED with symptoms that may signal an emergency, such as chest
pain, and clinicians are able to
rule out an emergency only after
performing an evaluation and diagnostic tests. Indeed, 88% of all
visits that are retrospectively determined to be for “nonemergency” (primary care treatable) diagnoses cannot be distinguished
from true emergencies at the
time of admission on the basis of
the patient’s chief complaint.4 It
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is neither ethical nor prudent for
clinicians to withhold care until
they can determine whether a
case is an emergency — and at
that point opportunities for cost
savings through diversion from
the ED would probably be
minimal.
Instead of requiring Medicaid
patients to pay for a portion of
their ED care, some states are
trying to provide them with better alternatives to the ED. This
strategy requires that beneficiaries have access to a primary
care provider who can help prevent exacerbations of chronic illnesses such as asthma that might
otherwise lead to acute crises.
Well-managed systems can also
provide prompt appointments to
patients with time-sensitive health
concerns that are not necessarily
emergencies — such as a persistent, moderate headache that
does not get better with over-thecounter medications.
At the core of this alternative
approach to reducing ED visits are
key components of the patientcentered medical home model,
including care coordination, case
management, extended hours,
and walk-in visits. Medical-home
initiatives emphasize prevention
and post-acute care, and preliminary studies have shown these
models to be effective in reducing ED use among Medicaid beneficiaries.5 The ACA includes an
optional program that gives states
additional funding to support
providers that develop “health
homes” for Medicaid beneficiaries with multiple chronic physical conditions or severe mental
illness. The program has been
adopted by 16 states to date. Successful utilization of medicalhome initiatives to reduce ED
visits will depend on access to
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providers who are willing to take
Medicaid patients. Among other
things, this approach will require
the establishment of new access
points for Medicaid beneficiaries
through the growth of community health centers; policies that
increase physician participation
in Medicaid, such as reimbursement at parity with Medicare
rates; and better support for participating practices, ranging from
financial incentives for providing
after-hours coverage, to shared
electronic health records, to integrated behavioral health services.
Medical homes can be augmented with other resources to
improve ease of use. For example, transportation is a common
barrier to receiving timely primary care for low-income patients, yet ironically states such
as Indiana that are seeking to
penalize patients for ED use have
used the same waiver process to
curtail nonemergency transportation. Facilitating access to non
emergency transportation — for
instance, by providing patients
with taxi vouchers, subway tokens, or paratransit access — is
critical, given that many Medicaid beneficiaries live in communities that lack such accessible
options as retail or urgent care
clinics.
Additional resources are also
needed for triaging patients’
health concerns and providing
care in alternative settings. Policymakers may look beyond the
United States for promising
models. France, for instance, triages callers to its “15” line (the
medical portion of its 911-equivalent) to a lay dispatcher or an
on-call physician who can provide medical advice over the phone.
If medical advice is insufficient,
the dispatcher can advise the pa-
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tient to see his or her primary
care physician or can dispatch a
physician to deliver care in the
patient’s home or send an ambulance. Differences in health system financing between the two
countries would make it difficult
to adopt this triage system wholesale in the United States. But
state Medicaid programs could
create financial incentives for
Medicaid managed-care organizations to provide a help line to
assist patients in choosing appropriate treatments and venues.
ED waiting rooms impose a
substantial time cost on people
seeking care, yet more patients
visit the ED every year. Burdening patients with a bill if the
cause of their visit is retroactively deemed not to have been an
emergency will probably prove
neither equitable nor effective in
directing patients to alternative
settings and could lead to unintended consequences if patients
avoid care out of fear of economic hardship. Given these ramifications and the ineffectiveness
of past attempts to impose costs
on Medicaid patients seeking ED
care, the Obama administration’s
decision to approve demonstration projects involving high cost
sharing and loss of transportation coverage is troubling. Instead, CMS might encourage
state initiatives to develop robust
ED alternatives. Although this approach requires more substantial
changes to the health care system,
it may be one of the most meaningful and sustained ways to
improve the care of all medically
or financially vulnerable Americans, especially Medicaid beneficiaries.
Disclosure forms provided by the authors
are available with the full text of this article
at NEJM.org.
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